Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma

Table 3 Univariate and multivariate survival analysis of clinicopathologic variables and miR-197 expression in diffuse large B cell lymphoma patients

Clinicopathologic variables	R-CHOP cohort, n = 43			ABC R-CHOP cohort, n = 31
	UA	MA		UA	MA
	p	p	HR [95% CI]	p	p	HR [95% CI]
miR-197
Low vs. high	0.036	0.031	27.9 [1.4–569.0]	0.025	0.037	21.5 [1.2–382.6]
IPI
High (3–5) vs. low (0–2)	< 0.001	0.009	10.0 [1.8–56.1]	0.001	0.055	5.1 [1.0–26.6]
B symptoms
Presence vs. absence	0.024	0.844	1.2 [0.3–4.8]	0.059
Bone marrow involvement
Presence vs. absence	0.006	0.038	15.4 [1.2–203.3]	0.029	0.046	13.5 [1.1–173.1]
Stage^a
I–II vs. III–IV	0.004			0.012
Performance status^a
≥ 2 vs. 0–1	< 0.001			< 0.001
LDH^a
Elevated vs. normal	0.005			0.005
Number of extranodal sites^a
≥ 2 vs. 0–1	< 0.001			0.002

UA univariate analysis, MA multivariate analysis, 95% CI 95% confidence interval, IPI international prognostic index, LDH lactate dehydrogenase
^aThese variables were not included in multivariate analysis due to their close relationship with IPI

ISSN: 1479-5876